{"id":"W4406437743","doi":"10.1093/braincomms/fcaf022","title":"Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials","year":2024,"lang":"en","type":"review","venue":"Brain Communications","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Medical Research Future Fund; UCB Pharma; National Institutes of Health; Department of Industry, Science, Energy and Resources, Australian Government; National Health and Medical Research Council; Eisai Canada; Biogen; Medical Research Council; Epilepsy Society; Eisai; U.S. Department of Defense; Australian Government; Multiple Sclerosis Australia","keywords":"Progressive supranuclear palsy; Disease; Medicine; Clinical trial; Physical medicine and rehabilitation; Neuroscience; Internal medicine; Psychology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003759214,0.000367992,0.002612937,0.0006045437,0.00005773277,0.00004245005,0.0005501235,0.0003246893,0.00002265259],"category_scores_gemma":[0.006427919,0.0002607406,0.001339516,0.0006768376,0.0002219877,0.00008019264,0.0003640201,0.0004683534,0.00002434636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000160132,"about_ca_system_score_gemma":0.001043196,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002211118,"about_ca_topic_score_gemma":0.00005117638,"domain_scores_codex":[0.9940495,0.00258598,0.002350008,0.0005226085,0.0002234619,0.0002683841],"domain_scores_gemma":[0.991068,0.005456717,0.0008518507,0.002236281,0.00009610393,0.000291053],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004481023,0.002600013,0.000654045,0.01222321,0.000760159,0.00006887698,0.00003905488,3.961943e-8,2.777494e-7,0.0008784899,0.002221617,0.9801061],"study_design_scores_gemma":[0.002406954,0.0002195133,0.001066695,0.0626924,0.004019652,0.000005266848,0.00002437348,0.0002224877,1.961565e-7,0.0003899013,0.9287409,0.0002116837],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001336805,0.9898217,0.00001004979,0.001079107,0.000122271,0.0076049,0.00111457,0.00004718065,0.00006650038],"genre_scores_gemma":[0.0007583255,0.9871054,0.006175789,0.00007193577,0.00004832467,0.003568295,0.002078282,0.0000900296,0.0001036219],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9798945,"threshold_uncertainty_score":0.9999845,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3678472055938017,"score_gpt":0.5514229934338847,"score_spread":0.183575787840083,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}